ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes in type 2 diabetics
This article was originally published in Scrip
Executive Summary
Hypolipaemic fenofibrates such as Abbotts' TriCor, its next-generation Trilipix and generics, do not improve cardiovascular outcomes in patients with type 2 diabetes when used in combination with simvastatin (Merck & Co's lipid-lowering Zocor). The much-awaited ACCORD LIPID data were presented this week at the American College of Cardiology (ACC) meeting in Atlanta and simultaneously published in the New England Journal of Medicine and show that the place of fibrates in diabetics is still unclear.